Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 6.4 |
| Analyst target | 4.0 |
SGHT · Why this verdict
Why Sight Sciences (SGHT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Sight Sciences carries a genuine earnings-beat catalyst, but a Rule-of-40 failure, sustained insider selling, and an already-reached valuation target with negative near-term asymmetry keep the setup unfavorable.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Sight Sciences has beaten consensus in 3 of the last 4 quarters with an average surprise of +26.6%, and the catalyst notes explicitly flag a strong earnings pattern (3 beats / 1 miss). Catalyst breakdown | The beat count should stay at or above 3 of the trailing 4 quarters through the next two reporting cycles. | ↑Improving |
| CounterLight analyst coverage (5.0 analysts) dampens the reliability of the estimate base, making the beat streak less statistically meaningful. | ||
Sight Sciences fails the Rule of 40 threshold (scoring 9 against the 40 bar), signaling growth plus profitability is well below the efficient-growth benchmark. Quality breakdown | The Rule of 40 score should rise above 20 over the next 12 months as growth or margin improves. | →Stable |
| CounterEarly-stage medical device commercialization often runs below Rule of 40 by design while investing in market access, without indicating a broken model. | ||
Insiders have been net sellers, with 6 sell transactions against 1 buy and a net reduction of 68,650 shares over the trailing 90 days, producing a bearish insider signal. Insider transaction read | The insider signal should shift toward neutral, with buy transactions increasing relative to sells, over the next 12 months. | →Stable |
| CounterRoutine pre-scheduled selling plans (Rule 10b5-1) among multiple insiders can produce a bearish-looking tally without reflecting a change in insider conviction. | ||
The stock has already reached its analyst price target with the V9 panel flagging a negative asymmetry ratio (-0.3), meaning downside risk now outweighs upside from current levels. Reward-to-risk math | The analyst price target should be revised upward by more than 10% over the next 12 months to restore positive asymmetry. | →Stable |
| CounterA negative near-term asymmetry reading doesn't preclude a longer-run re-rating if the earnings beat streak continues. | ||
Sight Sciences has beaten consensus in 3 of the last 4 quarters with an average surprise of +26.6%, and the catalyst notes explicitly flag a strong earnings pattern (3 beats / 1 miss).
↑ImprovingCatalyst breakdown
- Expectation
- The beat count should stay at or above 3 of the trailing 4 quarters through the next two reporting cycles.
CounterLight analyst coverage (5.0 analysts) dampens the reliability of the estimate base, making the beat streak less statistically meaningful.
Sight Sciences fails the Rule of 40 threshold (scoring 9 against the 40 bar), signaling growth plus profitability is well below the efficient-growth benchmark.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should rise above 20 over the next 12 months as growth or margin improves.
CounterEarly-stage medical device commercialization often runs below Rule of 40 by design while investing in market access, without indicating a broken model.
Insiders have been net sellers, with 6 sell transactions against 1 buy and a net reduction of 68,650 shares over the trailing 90 days, producing a bearish insider signal.
→StableInsider transaction read
- Expectation
- The insider signal should shift toward neutral, with buy transactions increasing relative to sells, over the next 12 months.
CounterRoutine pre-scheduled selling plans (Rule 10b5-1) among multiple insiders can produce a bearish-looking tally without reflecting a change in insider conviction.
The stock has already reached its analyst price target with the V9 panel flagging a negative asymmetry ratio (-0.3), meaning downside risk now outweighs upside from current levels.
→StableReward-to-risk math
- Expectation
- The analyst price target should be revised upward by more than 10% over the next 12 months to restore positive asymmetry.
CounterA negative near-term asymmetry reading doesn't preclude a longer-run re-rating if the earnings beat streak continues.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.1 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -10% of revenue
- ▸Rule of 40: 9 (fail)
Growth
7.4/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 7.4 |
Momentum
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 3.1 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.0 |
| erm sentiment | 5.0 |
Insider
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.9 |
| holder change | 4.6 |
| notable moves | 3.0 |
- ▸Modest insider selling — $379,619 (0.081% of mkt cap)
Peer rank
3.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.7 |
| quality rank | 1.0 |
| growth rank | 7.3 |
Technical
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.5 |
| support resistance | 1.2 |
| 52w position | 8.2 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 7.3 |
| volatility | 1.2 |
| implied vol | 0.0 |
| beta | 1.9 |
| debt equity | 6.2 |
- ▸High IV: 152%
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:5.4>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:66d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (2)
- MOMENTUM:5.4<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.46
Upside
-6.8%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 2.42>1.3, MCap $0.5B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's -0.5=NEGATIVE outcome against Growth at 7.4 and asymmetric R:R of -0.46.
The strongest dimensions are Growth at 7.4, Catalyst at 6.7, and Momentum at 5.4; the weakest are Quality at 3.4, Peer rank at 3.5, and Insider at 3.8. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.46 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak
Trip ifBeat count falls below 2 of the trailing 4 reported quarters over the next two earnings cycles.
- P2Rule Of 40 Failure
Trip ifRule of 40 score drops below 5, worsening from the current 9.
- P3Insider Selling Pressure
Trip ifNet insider share transactions rise above 0 shares over a trailing 90-day window, reversing the current -68,650 share net sell.
- P4Valuation Target Reached
Trip ifAnalyst price target rises more than 10% from current levels, restoring positive asymmetry from the current -0.3 ratio.